Nano-crystalline Megestrol Acetate is named as a drug or biological intervention in 3 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Changchun GeneScience Pharmaceutical Co., Ltd. (2) and Shandong Cancer Hospital and Institute (1). Registered phases: Not applicable, Observational and Phase 3. Conditions studied include Advanced Pancreatic Ductal Adenocarcinoma; Cancer Anorexia-Cachexia Syndrome; Cachexia.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06940102 | Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors (ClinicalTrials.gov ↗) Cachexia, Digestive System Cancer, Gastric Cancer |
Observational | Recruiting |
| NCT07408505 | Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer (ClinicalTrials.gov ↗) Advanced Pancreatic Ductal Adenocarcinoma, Cancer Anorexia-Cachexia Syndrome |
Not applicable | Recruiting |
| NCT06961188 | Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis (ClinicalTrials.gov ↗) Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity, Untreated With Systemic Therapy |
Phase 3 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Advanced Pancreatic Ductal Adenocarcinoma | 1 |
| Cancer Anorexia-Cachexia Syndrome | 1 |
| Cachexia | 1 |
| Digestive System Cancer | 1 |
| Gastric Cancer | 1 |
| Colorectal Cancer | 1 |
| Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity | 1 |
| Untreated With Systemic Therapy | 1 |
| Lead sponsor | Trials |
|---|---|
| Changchun GeneScience Pharmaceutical Co., Ltd. | 2 |
| Shandong Cancer Hospital and Institute | 1 |
| Register | Nano-crystalline Megestrol Acetate trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nano-crystalline Megestrol Acetate works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nano-crystalline Megestrol Acetate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.